Genzyme Corp insider trades: Bioenvision (BIVN) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Genzyme Corp reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 10, 2007 | BIVN | ↑ Buy | 8,706,644 | $5.60 | $48.8M | Direct | Jul 11, 2007 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Genzyme Corp's insider trades
Genzyme Corp is a 10% owner of Bioenvision (BIVN). Since Jul 10, 2007, it has reported 1 open-market purchase worth $48.8M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BIVN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.